AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Male Subjects With Type II Diabetes (T2DM)
Conditions
Male Subjects With Type II Diabetes (T2DM)
Trial Timeline
Dec 16, 2016 → Jan 8, 2018
NCT ID
NCT02935712About AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+Placebo
AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+Placebo is a phase 1 stage product being developed by AstraZeneca for Male Subjects With Type II Diabetes (T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT02935712. Target conditions include Male Subjects With Type II Diabetes (T2DM).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02935712 | Phase 1 | Completed |
Competing Products
20 competing products in Male Subjects With Type II Diabetes (T2DM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| [14C]-LY3549492 + LY3549492 + [14C]-LY3549492 | Eli Lilly | Phase 1 | 33 |
| CT-P41 + EU-approved Prolia | Celltrion | Phase 1 | 33 |
| CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx | Celltrion | Phase 1 | 33 |
| CT-P52 | Celltrion | Phase 1 | 33 |
| CT-P43 + CT-P43 | Celltrion | Phase 1 | 33 |
| Telmisartan + Amlodipine + Rosuvastatin | Yuhan | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6011 + E6011 Matching Placebo | Eisai | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| Eribulin Injection [Halaven] + Paclitaxel injection | Eisai | Approved | 85 |
| E3112 | Eisai | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Placebo + E3112 | Eisai | Phase 1 | 33 |
| [14C]-E6007 | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |